Novel pharmacotherapeutic targets for the management of drug addiction.
Despite individual variation in the liability to the abuse of psychoactive substances, there is substantial commonality shared by drugs of abuse. The knowledge of these common mechanisms together with the continued elucidation of the neurobiological underpinnings of withdrawal symptoms, drug intake, craving, relapse, and co-morbid psychiatric associations are critically important for the development of new therapeutic strategies. The present review will focus on recent advances in the development of innovative pharmacotherapeutic agents, which should promote higher efficacy (abstinence, prevention of relapse, long-term recovery) and patient compliance, as well as improved safety profiles.
Heidbreder
Christian
C
Department of Neuropsychopharmacology, Centre of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Pharmaceuticals, Via A. Fleming 4, 37135 Verona, Italy. Christian_A_Heidbreder@gsk.com
D006801:Humans; D016233:Immunotherapy, Active; D010349:Patient Compliance; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D055502:Secondary Prevention; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000534:rehabilitation; D013678:Technology, Pharmaceutical
D011619:Psychotropic Drugs